Proceedings from a CME symposium held during the 61st ASH Annual Meeting. Featuring perspectives from Drs Mark Levis, Daniel A Pollyea, Richard M Stone and Andrew H Wei.
Introduction
Program Overview: Dr Neil Love (00:00)
Evolving Paradigms in Up-Front Treatment for Older Patients or Those Ineligible for Intensive Chemotherapy
Case (Dr Pollyea): A woman in her mid-30s with acute myeloid leukemia (AML) who is unable to undergo intensive induction chemotherapy because of refusal to accept blood products on religious grounds achieves a complete response to venetoclax/azacytidine (11:28)
Case (Dr Pollyea): A women in her late 60s with AML who is ineligible for intensive induction chemotherapy receives venetoclax/azacitidine as first-line therapy (15:18)
Faculty Presentation: Dr Pollyea (19:39)
Assessment, Incidence and Clinical Significance of FLT3 Mutations in AML
Case (Dr Stone): A man in his mid-40s with AML with a FLT3-ITD mutation receives 7 + 3 induction in combination with midostaurin and undergoes allogeneic transplant (47:53)
Case (Dr Stone): A man in his early 60s who underwent allogenic transplant 1.5 years ago for high-risk myelodysplastic syndrome (MDS) presents with AML with a FLT3-ITD mutation and receives gilteritinib (50:46)
Faculty Presentation: Dr Stone (52:31)
Long-Term Treatment for Patients with AML with IDH Mutations
Case (Dr Levis): A woman in her mid-80s who previously received azacitidine and lenalidomide for MDS presents with AML with an IDH1 mutation and receives ivosidenib (1:13:52)
Case (Dr Levis): A man in his early 60s who is receiving enasidenib for AML with an IDH2 mutation develops differentiation syndrome causing acute kidney injury (1:19:11)
Faculty Presentation: Dr Levis (1:21:56)
Other Novel Agents and Promising Strategies Under Evaluation for Patients with AML
Podden och tillhörande omslagsbild på den här sidan tillhör Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av, eller tillsammans med, Poddtoppen.
